Our Pricing

Wegovy Dosage Chart: Your Complete Starter Dose Guide

Understanding the wegovy dosage chart uk protocol is essential before starting semaglutide treatment for weight management. At Cured Pharmacy, our UK-registered clinical team guides patients through the complete dose escalation schedule, from the 0.25 mg starter pen through to the 2.4 mg maintenance dose, ensuring safe and effective treatment outcomes.

Understanding the Wegovy Dosage Chart UK Protocol

Wegovy follows a structured five-step dose escalation protocol approved by the MHRA for weight management in the UK [1]. This gradual titration schedule minimises gastrointestinal side effects whilst allowing your body to adapt to semaglutide's appetite-suppressing effects. The standard wegovy dosing schedule uk begins with 0.25 mg weekly for four weeks, then increases monthly until reaching the therapeutic maintenance dose of 2.4 mg.

Clinical trials demonstrate that this graduated approach significantly improves treatment adherence compared to starting at higher doses [1]. In the STEP 1 trial, patients following the complete dose escalation achieved an average 14.9% body weight reduction over 68 weeks, with 86.4% of participants completing the full titration schedule [2]. Each dose level serves a specific purpose: lower doses establish tolerability, whilst higher doses deliver the full therapeutic effect on appetite regulation and metabolic function.

Wegovy Starter Dose: The 0.25 mg Foundation Phase

Your wegovy 0.25 mg starting dose represents the critical foundation phase of treatment. During this first month, you'll inject 0.25 mg subcutaneously once weekly, typically in the abdomen, thigh, or upper arm. This introductory dose contains approximately one-twelfth of the final therapeutic dose, allowing your GLP-1 receptors to gradually adapt to semaglutide's effects [1].

Most patients experience minimal side effects at this starter level, though mild nausea affects approximately 20% of users during the first two weeks [2]. The 0.25 mg dose initiates the medication's dual action on brain appetite centres and gastric emptying, but isn't sufficient for significant weight loss on its own. Think of this phase as priming your system for the therapeutic doses ahead, establishing tolerance patterns that will support your entire treatment journey.

What to Expect During Your First Month

During the 0.25 mg starter phase, you may notice subtle changes in appetite and food preferences, though dramatic weight loss isn't typical at this dose level. Our superintendent pharmacist Tarun Kumar advises patients to use this month to establish injection routines, identify optimal injection sites, and develop sustainable eating patterns that will maximise results once therapeutic doses begin. Any side effects experienced now typically indicate how you'll respond to higher doses, allowing your prescriber to adjust the escalation timeline if needed.

Complete Wegovy Dose Escalation Chart

The full wegovy dose escalation chart follows a five-month titration schedule before reaching maintenance dosing. Month one uses 0.25 mg weekly, month two increases to 0.5 mg weekly, month three advances to 1 mg weekly, month four reaches 1.7 mg weekly, and month five achieves the target 2.4 mg weekly dose [1]. Each increment represents a carefully calculated increase that balances efficacy against tolerability.

This structured escalation isn't arbitrary—it's based on pharmacokinetic data showing semaglutide reaches steady-state plasma concentrations after 4-5 weeks at each dose level [3]. Rushing through dose increases or skipping steps significantly raises the risk of persistent nausea, vomiting, and treatment discontinuation. In clinical practice, approximately 7% of patients require extended time at intermediate doses before advancing, and your UK prescriber can modify the standard schedule based on your individual response and tolerability [2].

The 2.4 mg maintenance dose delivers the full therapeutic effect observed in clinical trials. At this level, semaglutide produces sustained appetite reduction, delayed gastric emptying, and improved glycaemic control that together drive clinically significant weight loss [1]. Patients typically remain at 2.4 mg indefinitely, though some may reduce to 1.7 mg for maintenance if they've achieved weight goals and experience persistent side effects at the higher dose.

Adjusting Your Dosing Schedule

Whilst the standard escalation protocol suits most patients, individual circumstances may require modifications. If you experience severe gastrointestinal symptoms at any dose level, your prescriber may recommend staying at your current dose for an additional month before advancing. Conversely, patients with exceptional tolerance and no side effects occasionally ask about faster escalation—however, this approach isn't recommended, as it doesn't improve final outcomes and substantially increases discontinuation rates [2].

Wegovy Dosing Schedule UK: Timing and Administration

Wegovy's once-weekly dosing schedule offers significant convenience compared to daily injectable alternatives. You can administer your injection on any day of the week, at any time, with or without food—though maintaining the same day each week optimises steady-state drug levels [1]. If you miss a dose and it's been less than five days since your scheduled injection, take it as soon as you remember. If more than five days have passed, skip that dose entirely and resume your regular schedule with the next injection.

The subcutaneous injection technique is straightforward: pinch a fold of skin, insert the needle at a 90-degree angle, and press the pen button until you hear a click. Rotate injection sites weekly between abdomen, thigh, and upper arm to prevent lipohypertrophy (fatty lumps under the skin). Each Wegovy pen is pre-filled with a single dose and includes a hidden needle that automatically retracts after injection, making the process virtually painless for most patients.

Store unused Wegovy pens in the refrigerator at 2-8°C, but never freeze them. Once in use, a pen can remain at room temperature (up to 30°C) for up to 28 days, making it practical for travel. Always check the solution before injecting—it should be clear and colourless. Cloudiness, discolouration, or visible particles indicate the medication has degraded and shouldn't be used.

Semaglutide Dosing for Weight Loss: Clinical Evidence

Semaglutide's weight loss efficacy is directly dose-dependent, with the 2.4 mg weekly dose demonstrating superior outcomes compared to lower doses across all STEP trials [2]. In STEP 1, participants receiving 2.4 mg semaglutide lost an average 14.9% of baseline body weight over 68 weeks, compared to 2.4% in the placebo group—a statistically significant 12.5 percentage point difference [2]. Importantly, 86.4% of semaglutide-treated participants achieved at least 5% weight loss (the clinical threshold for health benefits), and 69.1% achieved at least 10% weight loss.

The mechanism behind semaglutide dosing for weight loss involves GLP-1 receptor activation in multiple tissues. At therapeutic doses, semaglutide crosses the blood-brain barrier to directly suppress appetite centres in the hypothalamus, whilst simultaneously delaying gastric emptying and reducing food intake [3]. These combined effects produce spontaneous calorie reduction averaging 500-800 kcal daily without conscious restriction—patients simply feel satisfied with smaller portions and experience fewer cravings between meals.

Long-term data from the STEP 4 trial demonstrated that continued treatment maintains weight loss, whilst discontinuation leads to gradual weight regain [4]. Participants who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight over the subsequent 48 weeks, highlighting that semaglutide functions as an ongoing treatment rather than a short-term intervention. This evidence supports the current UK prescribing approach of maintaining patients on 2.4 mg indefinitely, subject to ongoing clinical review and tolerability.

Comparing Semaglutide Doses Across Indications

It's worth noting that Wegovy's 2.4 mg dose differs from Ozempic's maximum 1 mg dose, despite both containing semaglutide. Ozempic is licensed for type 2 diabetes management, where lower doses sufficiently improve glycaemic control. Wegovy's higher dose was specifically studied and approved for weight management in individuals without diabetes, reflecting the dose-response relationship between semaglutide concentration and weight loss magnitude [1][2]. Using Ozempic off-label for weight loss at its maximum 1 mg dose produces approximately 60-70% of the weight reduction seen with Wegovy's 2.4 mg dose.

Starting Wegovy at Cured Pharmacy: Your Treatment Journey

Beginning Wegovy treatment at Cured Pharmacy starts with a comprehensive online clinical assessment that takes under three minutes to complete. Our UK-registered prescribers review your medical history, current medications, weight management goals, and any contraindications to semaglutide therapy. This assessment ensures Wegovy is clinically appropriate and safe for your individual circumstances, in accordance with MHRA prescribing guidelines and NICE weight management recommendations.

Once approved, your first prescription will be for the 0.25 mg starter dose, supplied as a four-week pack containing four single-use pens. We provide detailed injection technique guidance, side effect management strategies, and ongoing clinical support throughout your dose escalation journey. Wegovy is available from £79.00 at Cured Pharmacy, with transparent upfront pricing shown before your consultation—significantly lower than typical UK market rates. All medications are genuine UK-licensed products dispensed from our GPhC-registered pharmacy (9012511) with 100% discreet packaging and next-day delivery options.

Your treatment journey includes monthly prescription reviews as you progress through the dose escalation schedule. Our clinical team monitors your weight loss trajectory, side effect profile, and overall response to ensure optimal outcomes. If you experience any concerns during treatment—whether related to dosing, side effects, or injection technique—our pharmacists are available by phone at (+44) 116 4646009 during business hours for professional guidance and support.

Eligibility and Clinical Considerations

Wegovy is licensed in the UK for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea [1]. It's contraindicated in pregnancy, during breastfeeding, in patients with personal or family history of medullary thyroid carcinoma, and in those with multiple endocrine neoplasia syndrome type 2. Your prescriber will assess these factors during your consultation to ensure safe prescribing in accordance with UK clinical guidelines.

Scientific References

1. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/13799
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Knudsen, L. B., & Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology, 10, 155. https://doi.org/10.3389/fendo.2019.00155
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and is subject to availability and prescriber approval based on individual clinical suitability.